OBJECTIVE: To determine if insulin treatment combined with a generous protein intake would normalize whole-body protein kinetics and nitrogen balance in obese subjects with Type 2 diabetes mellitus when compared to obese nondiabetic subjects: 1) during weight-maintenance and 2) after a very low energy diet (VLED). DESIGN: Clinical intervention study of iso-followed by hypoenergetic feedings with or without exogenous insulin. SUBJECTS: Sixteen obese subjects with a body mass index (BMI) of 39 AE 4 kg/m 2 , with Type 2 diabetes mellitus (three men, six women) or without (one man, six women). MEASUREMENTS: Nitrogen¯ux rate calculated from the urine 15 N-urea enrichment by using the 60 h oral 15 N-glycine method, rates of protein synthesis and breakdown calculated from nitrogen¯ux on days 6±8 (and 13±15 in the diabetic subjects) of isoenergetic feeding and days 24±26 of a 1.9 MJ diet. RESULTS: With insulin therapy: 1) during isoenergetic feeding, in the hyperglycaemic diabetic subjects, nitrogen balance was signi®cantly less than in the obese controls (À0.6 AE 0.6 compared with 1.8 AE 0.9 g N/d, P 0.037) but became positive (2.6 AE 0.6 g N/d, P`0.05); nitrogen¯ux decreased and net protein synthesis increased from values different from those of the obese controls to values no longer different; 2) during the VLED, plasma glucose concentrations`7 mmol/L were achieved and maintained in all diabetic subjects. Nitrogen equilibrium observed in ®ve out of seven obese nondiabetic and four out of nine diabetic subjects was associated with no change in nitrogen ux from the euglycaemic isoenergetic studies, but with 17% and 23% lower rates of synthesis (P`0.05) and 7% and 15% lower rates of breakdown (NS) in nondiabetic and diabetic subjects, respectively. CONCLUSION: Suf®cient exogenous insulin to near-normalize glycaemia improves the altered protein metabolism in hyperglycaemic diabetic subjects during isoenergetic feeding, and restores nitrogen equilibrium better than with VLED alone. Protein metabolism is more sensitive to the state of diabetes control than is generally appreciated clinically'.
Introduction
The presence of diabetes mellitus can affect protein metabolism, and insulin is a key regulator of the response to nutrient intake in achieving net protein retention. 1 This consequence of diabetes has been demonstrated using a number of different approaches, in both Type 1 and Type 2 diabetes. Insulin deprivation in Type 1 diabetes is associated with elevated rates of leucine turnover and oxidation 2±5 that are not completely corrected by conventional insulin therapy. 2, 3, 5, 6 Thus altered leucine kinetics with poor glycaemic control suggest increases in rates of protein breakdown in insulin-sensitive tissues which are greater than those in protein synthesis, resulting in net protein losses. In contrast, data from studies in Type 2 diabetes have not consistently shown such abnormalities. For example, nitrogen equilibrium in obese Type 2 diabetic subjects was maintained in the face of hyperglycaemia and glycosuria. 7 Treatment for 36 days with a 30 g/d protein, very low energy diet (VLED) was associated with less cumulative nitrogen loss in moderately-hyperglycaemic Type 2 diabetic compared to heavier obese control subjects, with both groups never achieving nitrogen equilibrium and nitrogen loss relating to initial lean body mass. 8 Prior studies of the kinetics of protein metabolism showed no difference in postabsorptive leucine turnover and oxidation between conventionallycontrolled, insulin-treated obese Type 2 diabetic subjects, and age-and weight-matched obese nondiabetic subjects. Intensive insulin therapy suf®cient to normalize blood glucose in the diabetic subjects did not modify postabsorptive leucine¯ux and oxidation. 9 In lean subjects with Type 2 diabetes mellitus, postabsorptive leucine kinetics were unaffected despite the presence of impairment of insulin-mediated glucose disposal. 10 Such ®ndings led some authors to conclude that the sensitivity of leucine (or protein) metabolism to insulin may differ from that of glucose and fat metabolism. 9, 11 On the other hand, Umpleby et al 13 showed that the leucine oxidation rate was elevated both morning and evening in non-obese subjects with Type 2 diabetes mellitus studied diurnally. Furthermore, insulin's antiproteolytic actions were found to be impaired in upper-body obesity. 13 Since most published studies were performed in the postabsorptive state, their results cannot be readily extrapolated to the fed-fasted nonsteady-state that prevails in daily life. Therefore, we have chosen to use the oral stable isotope 15 N-glycine method that gives data that are`integrated' for fed and fasted states. Using this approach we have found whole-body nitrogen¯ux and rates of protein synthesis and breakdown to be greater in the hyperglycaemic obese Type 2 diabetic than in ageand weight-matched nondiabetic persons during a weight-maintaining regimen. 14, 15 After six weeks of a very palatable but low quality protein VLED, diabetes was associated with decreases in rates of synthesis and breakdown to levels not different from those in control obese subjects, but greater cumulative nitrogen losses occurred despite attainment of near normal plasma glucose concentrations. Furthermore, we found that restoration of normoglycaemia with exogenous insulin during isoenergetic feeding was associated with more positive nitrogen balance and 18±23% lower nitrogen ux, rates of protein synthesis ad breakdown compared to the hyperglycaemic state. However, a high-quality protein VLED capable of restoring nitrogen balance in control obese subjects was associated with greater rates of protein breakdown and negative nitrogen balance in diabetic subjects. 16 These studies employed the same relatively high protein intakes in all subjects. We concluded that fed-fasted protein metabolism was more sensitive to the state of insulinization than previously suggested by studies of the postabsorptive state.
As many variables affect the protein response, including protein intake, in the present study we adjusted the protein intake of each subject by giving 1.5 g/kg BMI 25 /d (that is, corrected for the weight that each subject would have at a body mass index (BMI) of 25 kg/m 2 ), to assure a generous intake. We tested whether this would affect nitrogen balance and approximate the kinetics of protein metabolism in the control subjects, despite hyperglycaemia, (that is to account for differences between our results and those with postabsorptive leucine kinetics). After the period of hyperglycaemia during isoenergetic feeding, exogenous insulin suf®cient to achieve euglycaemia was given, with the same diet, to test for an effect. Finally, we tested whether the response to a VLED would be the same as that of control subjects if euglycaemia was maintained with insulin therapy from the onset (keeping the protein intake the same as during the isoenergetic diet).
Research design and methods

Subjects and diet
Sixteen obese subjects with (`NIDDM', three male, six female) and without (`obese', one male, six female) Type 2 diabetes mellitus were admitted to the Clinical Investigation Unit of the Royal Victoria Hospital. Their clinical and anthropometric characteristics are shown in Table 1 . Of the 12 female subjects, four with diabetes and three without, were postmenopausal. Because of the duration of the study, it was dif®cult to control for phase of menstrual cycle in the BMI body mass index; WHR waist to hip ratio; VLED very low energy diet; FFM fat-free mass. * P 0.001 vs pre-VLED. Data are presented as mean AE s.e.m. a 9 obese subjects with Type 2 diabetes mellitus (three male, six female). b 7 obese control subjects (one male, six female).
Protein turnover and insulin treatment in Type 2 diabetes mellitus R Gougeon et al remaining subjects. However, for the three subjects in the obese group, the studies were undertaken during the same phase of the cycle, two during the follicular phase and one during the luteal phase. Each was informed of the nature, purpose and possible risks of the study, and consent was obtained according to the guidelines of the hospital Human Ethics Committee, which had approved the protocol. Their age range was from 20±55 y. Clinical and laboratory evaluations showed no evidence of hepatic, cardiovascular, hematologic, renal or pulmonary dysfunction or gout.
Poorly-controlled and insulin-treated subjects at risk of uncontrolled hyperglycaemia or ketoacidosis (during discontinuation of therapy) and persons with established complications of diabetes were excluded. No other medications were taken during the study. The subjects did not smoke during the study and were con®ned to the sedentary life of the hospital ward with no other exercise. At least three days prior to admission, oral hypoglycaemic agents were stopped in those subjects previously receiving them. All subjects consumed a weight-maintaining liquid-formula diet, with casein and soy as protein sources (Ensure R , Ross Laboratories, Montreal, QC, Canada) supplemented with a casein-soy, all protein formula (Bariatrix International Inc., Lachine, QC, Canada) and with a glucose polymer (Polycose R , Ross Laboratories). The obese group took it for eight days and the NIDDM group took it for 16 days to provide the energy requirement calculated from the resting metabolic rate, according to the Harris-Benedict equation, 17 multiplied by 1.5. Protein intake was 1.5 g/kg BMI 25 /d. The reference body weight for this study was de®ned as the weight in kg that would correspond to a BMI of 25 kg/m 2 for each subject. This would therefore represent the individual body weight at the upper end of the generally-accepted as normal range for BMI. Protein intake therefore ranged between 80±125 g/d among subjects. Energy intake was adjusted in the hyperglycaemic NIDDM group by addition of glucose polymer according to the quantitatively-determined urinary glucose losses on the previous day.
Macronutrient energy distribution of weight-maintaining diets is given in Table 2 . All subjects then received a formula diet of mostly protein (Bariatrix International Inc.), at the same intake as during the isoenergetic diet, for the subsequent 27 days. The protein was casein-soy, palatably¯avored and presented as`cream' soup and pudding, which also provided 10±15 g carbohydrate and 2 g fat and represented an average of 1.93 MJ (460 kcal)/d. The total daily amino acid intake was 100 AE 3 g/d of which 46% were essential; its amino acid content has been reported previously. 14, 18 The subjects were given one tablet of a multivitamin, multimineral supplement (Centrum Forte, Cyanamid Canada, Inc., Montreal, QC, Canada) and 20 mmol of potassium as potassium chloride (K-DUR R , Key, Schering Canada Inc., Pointe-Claire, QC, Canada) each day. They received the formulas in six equally divided portions. Water intake was at least 1.5 L/d, and no other beverages were allowed. On day 28, the subjects were fed as previously described, 19 with a 3.35 MJ (800 kcal)/d diet composed of regular foods with a low carbohydrate content to minimize water retention. The subjects were taught the essentials of, and recommended to follow, a diet providing 4.6 MJ (1100 kcal)/d upon completion of the study. Oral hypoglycaemic medication was reinstated for some subjects as dictated by frequent capillary blood glucose determinations.
Insulin administration was as follows. A single dose of Humulin N (18±44 units) was given at 20:00 h and three doses of Humulin R given before meals at 08:00, 14:00 and 17:00 h (Eli Lilly Canada Inc., Scarborough, ON, Canada). The latter doses were adjusted according to the concurrently measured capillary glucose concentration. Progressive increments in doses were required during isoenergetic feeding and decrements in doses during the VLED.
During hospitalization, blood pressure and pulse were monitored twice daily with subjects lying and standing. Body temperature was taken every morning using a basal thermometer. Capillary blood glucose was measured 4±6 times/d using the Chemstrip bG and Accuchek II meter system (Boehringer Mannheim, Montreal, QC, Canada). Urine collections were made once a day. Body weight was measured on a balance calibrated to 0.1 kg (Scale-Tronix digital scale, Ingram and Bell-Meditron, Le Groupe Inc., Don Mills, QC, Canada). Water intake and urine ketones were recorded daily (Chemstrip Ug 5000, Boehringer 20 Body circumference measurements were taken at the site giving the minimal value between the xiphoid process and the iliac crest for the waist and at the level of greatest protuberance in the trochanteric region for the hips.
Procedures and isotope studies
The [ 15 N] glycine kinetic studies of protein metabolism were performed twice for the obese group and three times for the NIDDM group, on days 5±7 (and 13±15 in diabetic subjects) of isoenergetic feeding and on days 24±26 of the VLED starting at 08:00 h on day 1 and ending at 20:00 h on day 3. Ninety-nine atompercent excess [ ] glycine, in containers with hydrochloric acid as preservative. They were analyzed for urea nitrogen. Urea nitrogen was isolated, after removal of ammonia and other nitrogenous compounds with an ion-exchange resin, by using urease (U1500; Sigma, St Louis, MO) and a Conway procedure. 21 15 N enrichment of urea nitrogen was measured with a dual-inlet, triple-collector isotope-ratio mass spectrometer (Vacuum Generators, Isomass 903D, Cheshire, UK) and enrichment curves were drawn for each subject. Enrichment was corrected for background values determined by a urine sample taken immediately before each test. The method requires that the abundances of 15 N in urinary urea have reached a plateau within 60 h. The mean plateau value was calculated from measurements of 15 N abundance in 4±6 sequential samples determined to be at isotopic steady state. The rate of entry of nitrogen into the metabolic nitrogen pool was calculated from the mean plateau value, assuming that the fraction of the administered isotope that is excreted as urinary 15 N is the same as the fraction of total amino nitrogen entering the metabolic pool excreted as urinary urea nitrogen. 22±25 Compared with the ammonia end product, urea does not underestimate the synthesis rate. 24 The ammonia end product was not used in this study, because we also found that an isotopic steady state was dif®cult to de®ne in this pool during a VLED. Increases in urinary ammonia excretion in response to the acidosis associated with the ketogenic diet and the diurnal changes related to meals, affected urinary ammonia labeling. 25, 26 Nitrogen intake is known and total urinary nitrogen was measured. Thus, protein synthesis and breakdown were calculated from the Picou Taylor-Roberts 27 equation:
where Q is nitrogen¯ux, I is nitrogen intake, B is protein breakdown, S is protein synthesis and E is total urinary nitrogen.
Analytical methods
Venous blood samples were drawn from subjects with minimal stasis, in the overnight-fasted state on day 1 and day 3 of each [
15 N] glycine study and at the end of each week of the VLED. The samples were processed, centrifuged and stored as detailed previously.
14±16 Perchloric acid supernatants were assayed for 3-hydroxybutyrate and acetoacetate were measured by enzymic micro-¯uorometric methods;
28 plasma free fatty acids by a radiochemical method;
14±16 insulin by single-antibody radioimmunoassay and glucagon by double-antibody radioimmunoassay. 29 The insulin assay gives immuno reactive insulin (IRI) values in the diabetic subjects that are somewhat lower than those obtained with an insulin-speci®c assay from Linco Research Inc, St Louis, that is, it does not pick up proinsulin (unpublished results). Complete blood counts, glycated haemoglobin, and urea, lipid, creatinine and electrolyte determinations were by standard automated techniques in the hospital clinical laboratory. Aliquots of the 24 h urine collections were analyzed daily for urea, creatinine and electrolytes and frozen at À20 C until assayed for nitrogen components. Breath acetone was measured daily in the overnight-fasted state using an automated gas chromatograph (Diet Monitor R , Call Detect Inc., Richmond, CA).
Daily urinary ammonium nitrogen was measured with a speci®c ion electrode (Orion Research Inc., Cambridge, MA). Total urinary nitrogen was measured by chemiluminescence (Antek Pyro-Chemiluminescent Nitrogen System, Houston, TX). Calculation of daily nitrogen balance was based on the measured intake minus the measured urinary total nitrogen, pooled fecal nitrogen from subjects of other similar studies (66 mg/g N intake/d, n 9 during weight maintenance; 17 mg/g N intake/d, n 3 with VLED) and estimated skin, hair, and secretion (5 mg/kg body wt) losses. 30 Urinary 3-methylhistidine excretion was measured every 24 h by reverse phase high pressure liquid chromatography, 31 (Waters Ltd., Milford, MA), using a 23% acetonitrile solution as the mobile phase and¯uor-escamine as the¯uorogenic reagent (ICN Biochemicals Inc., Aurora, OH).
Resting energy expenditure (REE) was measured each week in strictly standardized conditions using a ventilated hood indirect calorimeter (Deltratrac TM Metabolic Monitor, Sensormedics Corporation, Anaheim, CA). Calculation of 24 h REE was made according to the de Weir equation. 32 The coef®cient of variation for the data used for the calculations was 3.9 AE 0.2% (n 56). Estimates of fat free mass (FFM) were made using BIA results for the weight maintenance period of the protocol from which the lean tissue losses calculated from cumulative nitrogen losses were subtracted.
Statistical methods
The data were analyzed by analysis of variance (ANOVA) using a repeated-measures design. Calculations were made with the Primer Biostatistics (McGraw Hill Inc., Montreal, QC, Canada). Signi®-cant differences (P`0.05) were identi®ed by the Student Newman-Keuls multiple range test. Intergroup comparisons were performed using unpaired ttests. Linear regression analysis was used to calculate correlation coef®cients. Data in text, ®gures and tables are presented as mean AE s.e.m.
Results
In the NIDDM group, weight decreased signi®cantly (P`0.05) during the isoenergetic diet with hyperglycaemia and increased with insulin therapy and normalization of glycaemia (vs day 8, P`0.05), such that at day 15 it did not differ from day 1 (Figure 1 ). In the obese control group, it decreased on day 1 and then was maintained. At the end of the VLED, weight loss averaged 9.3 AE 1.0 in the NIDDM group and 9.6 AE 0.9 kg in the obese group and losses of lean body mass (LBM) were 1.9 AE 0.4 and 1.6 AE 0.5 kg, respectively, NS ( Figure 1 , Table 1 ). The decrease in the waist to hip ratio (WHR) with the VLED was signi®cant (P 0.001) only in the NIDDM group (Table 1) . Both diet formulas were well tolerated. Resting electrocardiograms and liver function tests showed no alteration of clinical or physiological signi®cance. In both groups, there was no signi®cant change in serum alkaline phosphatase, total protein or albumin, hemoglobin or hematocrit (data not shown). As reported in previous studies 13, 14 the decrease in counts of total white blood cells (by 14%) and neutrophils (by 20%) with the VLED was signi®cant in both groups (P`0.05). Serum sodium, chloride, potassium and magnesium concentrations did not change (not shown). Venous blood pH and blood bicarbonate decreased signi®cantly (P`0.05) in both groups with the VLED (Table 3, Table 4 ). Serum urea decreased signi®cantly with insulin treatment in the NIDDM group, then increased signi®-cantly (P`0.05) with the VLED in both groups, but remained at all times within the normal range ( Table  3, Table 4 ). In both groups, mean serum uric acid was greater with the VLED than during isoenergetic feeding (P`0.05), especially early on, then tended to decrease at week 4, but this was signi®cant in the obese group only. There were no differences between groups in uric acid or its responses. Serum total cholesterol decreased signi®cantly in the NIDDM group (P`0.05) at week 2 and in the obese group at week 1 of the VLED into values lower than those during isoenergetic feeding, and remained at lower values throughout. However, during the VLED, serum cholesterol was higher in the NIDDM compared with the obese control group at all time points. Serum triacylglycerol was above the normal range (0.6± 2.3 mmol/L) initially for the NIDDM group. It decreased (P`0.05) with insulin therapy in the NIDDM subjects, and in both groups it declined (P`0.05) with the VLED to remain at these lower values thereafter in all subjects (Table 3, Table 4 ).
The NIDDM group postabsorptive serum glucose decreased signi®cantly (P`0.05) from hyperglycaemic concentrations during insulin therapy (Table 3 and Figure 2a ). Euglycaemia (fasting glucose 5.4 AE 0.3 mmol/L) was achieved in six subjects. Glycaemia remained normal or near normal in response to the combined VLED and insulin treatment. Mean daily glucose, based on the capillary blood glucoses, showed a comparable trend ( Figure  2a) . Glycaemia was stable during the [ 6635 AE 496*,***** *P`0.05 vs isoenergetic; **P`0.05 vs isoenergetic; ***P`0.05 vs isoenergetic insulin treatment; ****P`0.05vs VLED week4; *****P`0.05 vs VLED week 1; ******P`0.05 vs VLED weeks 3.
REE resting energy expenditure; VLED very low energy diet. Protein turnover and insulin treatment in Type 2 diabetes mellitus R Gougeon et al that level. Insulin was started (or doses were increased) to achieve euglycaemia for the period during which the second protein turnover studies were undertaken. The doses given were 109 AE 11 U/ d on day 9, 140 AE 17 U/d on day 13 and 148 AE 19 U/d on day 15, at which time they ranged from 58±212 U/d (see Figure 3) . During the VLED, exogenous insulin doses were reduced to 23 AE 4 U/d on day 1. Insulin was stopped in one subject on day 4 and in three others during week 2 of the diet. The other ®ve subjects received 23 AE 3 U/d (54 AE 8% as NPH and 46 AE 8% as regular) for the duration of the VLED treatment. Fasting plasma glucagon concentrations decreased slightly with insulin treatment from 24 AE 2 to 20 AE 2 pmol/L (P`0.05), and remained at that level during the VLED. The molar ratio of glucagon to insulin which was signi®cantly lower (P`0.05) during isoenergetic feeding with the insulin treatment (because of the increment in plasma insulin concentrations), increased with the VLED as plasma insulin decreased (0.12 AE 0.02 without insulin, 0.07 AE 0.01 with insulin, and 0.17 AE 0.02 post VLED).
In the obese control group, serum glucose decreased signi®cantly with the VLED and was signi®cantly lower (P`0.05) at all time points than in the NIDDM group (Table 4) . Insulin decreased (P`0.05) with the VLED from 197 AE 12 to 106 AE 12 pmol/L and was not different from that in the NIDDM group. Glucagon concentrations did not change as an effect of the VLED (24 AE 2 compared with 23 AE 2 pmol/L) but the glucagon to insulin ratio increased, due to the decrease in insulin concentrations (0.11 AE 0.01 vs 0.20 AE 0.03, P`0.05). The glucagon to insulin ratio was only signi®cantly greater (P 0.02) than for the NIDDM group during isoenergetic feeding when euglycaemic.
Plasma fatty acids were markedly elevated during hyperglycaemia, and decreased signi®cantly (P`0.05) during isoenergetic feeding with insulin treatment, then increased (P`0.05) in response to the VLED. Both during insulin treatment (isoenergetic) and throughout the VLED, fatty acids did not differ signi®cantly from the values in the obese group (Table 3, Table 4 ). Blood 3-hydroxybutyrate was higher during hyperglycaemia, decreased signi®cantly with insulin treatment during weight maintenance in NIDDM, then increased (P`0.05) with the VLED reaching a ten-fold increment by week 4 of the diet. This VLED response was the same in both groups. Blood acetoacetate followed a similar pattern of response (Table 3, Table 4 ). Similarly, mean breath acetone decreased with insulin treatment for the NIDDM group and increased progressively and comparably in both groups from initial values during isoenergetic feeding, in response to the VLED and remained elevated until refeeding. Urine 3-hydroxybutyrate was greater (P`0.05) in hyperglycaemic NIDDM subjects compared to the normoglycaemic period and signi®cantly greater (P`0.05) at week 1 Figure 2 Fasting plasma glucose (FPG) and mean capillary blood glucose (MCG) (Panel A) and fasting plasma insulin (Panel B) in NIDDM subjects (see text) during 14 days of isoenergetic feeding without insulin (day À14 to day À7) and with insulin starting at day À7 and during 27 days of very low energy diet (VLED), and in obese control subjects (see text) during 7 days of isoenergetic feeding and 27 days of VLED. Data are plotted as mean AE s.e.m. a P`0.05 vs hyperglycaemic during isoenergetic feeding; b P`0.05 vs isoenergetic feeding; c P`0.05 vs obese during isoenergetic feeding. Figure 3 Mean daily nitrogen balance during 14 days of isoenergetic feeding without (day À14 to day À7) and with insulin (day À7 to day À1) in NIDDM subjects (see text), from day À7 to day À1 in obese subjects (see text), then during 27 days of a very low energy diet (VLED) in both groups. Mean insulin doses given to the NIDDM subjects for the periods between the vertical lines are presented. a P`0.05 vs ISO in OBESE; b P`0.05 vs day À14 to day À7 and VLED in NIDDM; c P`0.05 vs ISO day 1±14 in NIDDM. Data are plotted as mean AE s.e.m.
Protein turnover and insulin treatment in Type 2 diabetes mellitus R Gougeon et al of the VLED than isoenergetic feeding, remaining at that level throughout. It did not differ between groups. In NIDDM, urine glucose excretion was considerable during the hyperglycaemic, compared with the insulin treatment periods, then remained at insigni®cant levels throughout the VLED (Table 3) . Urine creatinine did not change during the isoenergetic feeding, it decreased slightly but signi®cantly (P`0.05) with the VLED by week 3 in the obese control group (Table 4) and remained an average of 8% lower thereafter. For the NIDDM subjects, the decline in urine creatinine became statistically signi®cant only by week 4 of the VLED (Table 3 ). There were no signi®cant changes or intergroup differences in serum creatinine (not shown).
Nitrogen balance
In NIDDM, cumulative nitrogen balance over the ®rst seven days was À0.4 AE 4.0 g N; it did not differ from zero. Nitrogen balance was not signi®cantly different from the obese control group whose cumulative nitrogen balance over the seven days of isoenergetic feeding with comparable protein intake was 8.6 AE 3.5 g N. Nitrogen balance changed signi®-cantly in a positive direction over the subsequent seven days with insulin ( Figure 3 ) and the cumulative gain (19.8 AE 2.1 g N) observed was greater (P`0.05) than that of the obese control group even accounting for the decrease in urea pool indicated by the decrease in serum urea with insulin therapy. The latter could represent an average of 3.4 g N, using 0.60 L water/kg body weight as the space of distribution. On day 27 of the VLED, cumulative nitrogen loss in the NIDDM group did not differ signi®cantly from that of the obese control group (À53 AE 15 vs À58 AE 22 g N) even when the increase in urea pool is accounted for. This cumulative loss represtented 331 vs 362 g protein or 1.66 vs 1.81 kg lean tissue, a value not different from that measured with BIA (Table 1) , that amounted to 18% of weight loss. Mean nitrogen balance was the most negative from day 3±day 5 of the VLED but returned progressively toward a value that was not different from zero by the end of the diet in both groups (Figure 3 ). Urinary ammonium nitrogen was low during isoenergetic feeding but in the NIDDM group it decreased signi®cantly with insulin treatment (from 0.37 AE 0.04 to 0.23 AE 0.03 g/d, P`0.05). Neither of these differed signi®cantly from ammonium nitrogen in the obese control group (0.26 AE 0.04 g/d). Ammonium nitrogen increased to 0.64 AE 0.07 g/d (46 AE 5 mmol/d) by day 8 of the VLED, and remained at that level in both groups throughout. Urinary 3-methylhistidine excretion did not differ signi®cantly in the NIDDM group whether hyperglycaemic (2.5 AE 0.3) or euglycaemic (2.7 AE 0.2), compared to the obese control group (3.3 AE 0.4 mmol/ kg FFM/d) during isoenergetic feeding. With the VLED, it decreased signi®cantly (P`0.05) and comparably in both groups on day 27 to 2.210.25 in the NIDDM group and 1.98 AE 0.21 mmol/kg FFM/d in the obese control group. If excretion is expressed per day rather than per kg/FFM, there were again no differences related to glycaemia or between groups during isoenergetic feeding, and a signi®cant decrease during the VLED in both (data not shown). Figure 4 . During isoenergetic feeding, mean rates of whole-body nitrogen¯ux, Q, expressed as mg Á kg FFM À1 Á d À1 in hyperglycaemic NIDDM subjects, were signi®cantly greater (P`0.05) than in the obese control group. With intensive insulin treatment, mean nitrogen¯ux did not decrease signi®cantly in the whole group of NIDDM subjects, but was no longer statistically different from the obese control group. However,¯ux did decrease signi®cantly in the four NIDDM subjects who had not been treated with insulin during the hyper- Figure 4 Whole-body protein kinetics measured by the [
Kinetics of protein metabolism
15 N]glycine method during isoenergetic feeding and at the end of 27 days of VLED (`post VLED'). Q nitrogen¯ux; S rate of protein synthesis; B rate of protein breakdown; [S±B] net protein synthesis. For the NIDDM subjects (see text) during the isoenergetic diet period, the values during hyperglycaemia are presented in the closed bars, and those during insulin treatment (euglycaemic) in open bars. Data are shown as mean AE s.e.m. a P`0.05 vs corresponding values in the obese nondiabetic subjects during isoenergetic feeding. b P`0.05 vs corresponding values in NIDDM euglycaemic during isoenergetic feeding. c P`0.05 vs corresponding values in NIDDM hyperglycaemic during isoenergetic feeding.
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, P 0.046. In these four subjects, rates of protein breakdown also decreased signi®-cantly (P 0.049) from 700 AE 91 to 540 AE 49 mg
. The rate of synthesis (S) and breakdown (B) did not change signi®cantly in the whole group with insulin treatment but net protein synthesis [S±B] increased signi®cantly (P`0.05). Rates of breakdown were greater in the NIDDM group, hyperglycaemic and euglycaemic, compared to the obese control group (640 AE 49 and 598 AE 41 compared to 470 AE 29 mg N Á kg FFM À1 Á d
À1
, P`0.05). Rates of synthesis were also greater in the NIDDM hyperglycaemic and euglycaemic compared to obese control group (670 AE 52 and 670 AE 43 compared to 530 AE 33 mg N Á kg FFM À1 Á d À1 , P`0.05) (Figure 4 ). In the hyperglycaemic NIDDM subjects, the difference between the rates of protein synthesis and those of breakdown (net synthesis) were such that [S±B] was lower (P 0.040) than in the obese control group. Protein intake ranged from 80±125 g/d in all subjects. There was a positive correlation between intake and nitrogen¯ux, expressed per kg body weight: r 2 0.414, P 0.007, n 16, with isoenergetic feeding in the obese control and the NIDDM groups when euglycaemic ( Figure 5) .
With the VLED, nitrogen¯ux did not change signi®cantly in either group (when the NIDDM subjects were compared with the data for euglycaemia). In the NIDDM group, the rates of synthesis decreased (P`0.05) compared with the rates during both the isoenergetic hyperglycaemic and the euglycaemic periods. Those of breakdown decreased signi®cantly only when compared with the rates when the subjects were hyperglycaemic. Met protein synthesis decreased post-VLED. In the obese, protein synthesis decreased signi®cantly (P 0.002) with the VLED compared with isoenergetic feeding but breakdown did not change (P 0.254) such that net synthesis was signi®cantly lower. The positive correlation between protein intake and nitrogen¯ux remained post VLED: r 2 0.557, P 0.001, n 16. However, there were no correlations between cumulative nitrogen loss and any one of protein intake, energy intake or initial BMI.
Resting energy expenditure (REE) 
Discussion
Our results indicate that insulin therapy can lower abnormally elevated nitrogen¯ux and protein breakdown in hyperglycaemic subjects in parallel with its effect on improving glycaemia toward values not different from those of nondiabetic obese subjects. This suggests that the magnitude of underinsulinization that characterized our moderately hyperglycaemic diabetic subjects, causes alterations in the integrated daily protein metabolism (including fed and fasted states). We have previously found that intensive insulin therapy, during isoenergetic feeding, was associated with nitrogen retention and a decrease in protein turnover, after a period of hyperglycaemia without treatment, but using lower protein intakes. 16 Despite a generous protein intake (based on height, since it was given based on weight at a BMI 25 ), the present hyperglycaemic diabetic subjects showed a trend toward less nitrogen retention than the nondia- Figure 5 Correlation between the nitrogen¯ux (mg N/kg body weight) and protein intake (g protein/kg body weight) during isoenergetic feeding in euglycaemic NIDDM (see text) and obese (see text) subjects.
Protein turnover and insulin treatment in Type 2 diabetes mellitus R Gougeon et al betic group and a signi®cant increase in retention with insulin treatment. Although [S±B] increased with insulin therapy in all subjects, nitrogen¯ux and protein breakdown decreased signi®cantly in only four subjects. In the other ®ve subjects in whom glucose concentrations decreased as well, there were no changes in nitrogen¯ux. Furthermore, Q and B tended to be lower in this latter group. What distinguished the latter subset was that they were the ones who received small doses of insulin to prevent glucose concentrations from becoming greater than 20 mmol/ L during the hyperglycaemic period. This absence of response is reminiscent of the results for the studies of leucine kinetics in the postabsorptive state reporting no difference in proteolysis in Type 2 diabetic subjects treated with insulin whether poorly or better controlled. 9 Improved glycaemia with oral sulfonylurea therapy 33 or with intensive insulin treatment, 9, 33 were also reported not to affect leucine metabolism. These results were interpreted as indicative of a differential sensitivity of insulin's action on carbohydrate and fat vs protein metabolism. Our results suggest that a small dose of exogenous insulin may indeed affect nitrogen¯ux even if glycaemia is far from normalized. The fact that injected insulin reaches the systemic circulation rather than the liver ®rst, raises the possibility that insulin's effects on protein are greater if delivered systemically. Increasing the insulin dose suf®ciently to induce euglycaemia in this subset increased nitrogen¯ux, rates of synthesis and breakdown, but net protein synthesis and nitrogen retention as well. The absence of change in 3-methylhistidine excretion suggests that the greater protein retention is not due to a decrease in muscle proteolysis. Others have also reported no signi®cant change in its excretion with improved glycaemia in Type 2 diabetes. However, in Type 1 diabetes, intensive insulin administration has been associated with a decrease in muscle protein loss as estimated by 3-methylhistidine excretion. 34 Compared to our previously-studied hyperglycaemic subjects, we found that during the earlier isoenergetic studies a higher mean protein intake of 93 g or 1.36 AE 0.02 g/kg at BMI 25 14,15 However, further increasing dietary protein to 99 g or 1.5 g/kg at BMI 25 This suggests there is a threshold of protein intake at which increasing intake will increase [S±B] despite hyperglycaemia being present. Notwithstanding, [S±B] remained lower in the hyperglycaemic NIDDM subjects consuming the same generous protein intake as in the nondiabetic obese subjects. Thus it appears that diabetic control (as de®ned by glucose levels) overrides protein intake in determining protein retention. On the other hand, in diabetic and nondiabetic obese subjects, the amount of dietary protein appears to in¯uence the rates of nitrogen ux as indicated by its positive correlation with protein intakes (see Figure 5 ). Increasing protein from 12±21% of total energy intake was associated with increased rates of whole body protein turnover in elderly subjects. 35 Similar effects have been shown in young adults. 36 What are the implications of elevated nitrogen¯ux and protein metabolism? It has been speculated that increased protein turnover associated with higher dietary protein intakes may better equip an individual to respond to`unfavorable' states such as during energy and protein restrictions or catabolic stress. 35 Increasing protein intake has been postulated to potentially bene®t the elderly in whom skeletal muscle contribution to whole-body protein metabolism may be lower. 35, 37 Our results suggest it may assist hyperglycaemic Type 2 diabetic subjects with elevated rates of protein breakdown in a fed-state 15, 16 to maintain nitrogen equilibrium. The generous protein intake may have contributed to an absence of effect of insulin treatment in our whole group, and may account for the results of Staten et al 9 whose subjects consumed a diet of approximately 100 g protein.
We 16 and others 38±40 have reported that hyperglycaemia is associated with a higher REE. In the present study, REE decreased by 7% with insulin treatment to levels closer to those of our obese control group. The lower REE with insulin therapy has been related to the decline in blood glucose concentration 39, 40 enhanced peripheral glucose disposal 39 and a decline in protein turnover 16, 36, 38 that may be associated with a decrease in gluconeogenesis. REE has been reported to correlate with leucine¯ux (an index of proteolysis) and the nonoxidized portion of leucine¯ux, 40±42 processes which are energy-requiring.
All our diabetic subjects showed an android pattern of obesity based on WHR (Table 1) . WHR and visceral fat mass are highly correlated and visceral fat mass shows strong correlation to insulin resistance. 43 It has been suggested that with central obesity, a greater fraction of circulating fatty acids may derive from visceral adipocytes which show a low responsiveness to the antilipolytic effect of insulin, and more sensitivity to lipolytic stimuli. 44 Elevated concentrations of fatty acids cause insulin resistance in muscle and liver and increase hepatic gluconeogenesis. Plasma fatty acid concentrations were elevated during isoenergetic feeding with hyperglycaemia, suggesting increased lipolysis and a resistance to the antilipolytic action of insulin. 45 REE tended to be greater in the subjects with high WHRs. The correlation between initial REE and WHR was signi®cant (r 2 0.344, P 0.022, n 15). An effect of body fat distribution on REE has been shown by some, 44 but not all authors, 45 the discordance in results being attributed to greater FFM in the android subjects tested. As reported earlier, 16 RQ was lower in our hyperglycaemic diabetic subjects than in nondiabetic subjects during isoenergetic feeding, (0.76 AE 0.02 vs 0.85 AE 0.01, P`0.05) and increases signi®cantly with insulin therapy, to 0.81 AE 0.01, P`0.05, concomitant with a decrease in plasma fatty acid concentrations. These effects are consistent with better glucose disposal.
During the VLED, nitrogen balance progressively returned to equilibrium in four of the nine diabetic subjects. In the others, it was never reached, but the group's nitrogen balance did not differ from zero nor from that of the nondiabetic obese group. Furthermore, the whole group's cumulative negative nitrogen balance (À53 AE 15 g) was less than what we have observed in previous studies using the same casein VLED, but without insulin [À100 AE 12, n 6, P 0.049] 16 or a collagen-based VLED without insulin [À94 AE n 7, P`0.005].
15 By week 2 of the VLED, during which insulin had been given to all subjects, the difference in cumulative nitrogen losses was also striking compared to our previous study without insulin (À35 AE 7 vs À66 AE 10 g N, P 0.039), with comparable protein intake.
These smaller nitrogen losses during the VLEDs that we attribute to insulin treatment in the NIDDM group and to glycaemias being maintained at nearnormal concentrations throughout, occurred in a setting of comparable increases in ketone body and fatty acid concentrations in the NIDDM and obese control groups (Table 3, Table 4 ). Thus, with near-normalization of plasma glucose and other insulin-regulated metabolites in all subjects, the prevailing insulin concentrations and their effectiveness suf®ced to restrain net protein catabolism, and to maintain protein synthesis, during the VLED at levels comparable to those of persons without diabetes. Insulin therapy enhanced the protein-sparing effect of the VLED for the duration of the diet, as evidenced by cumulative nitrogen losses, [S±B] , and 3-methylhistidine excretion comparable to those of the nondiabetic group. As postulated above for the possible effects of small amounts of insulin during hyperglycaemia, perhaps these small doses of insulin during VLED had important physiological effects via their systemic (vs portal) delivery.
In conclusion, we have shown that during rather high protein isoenergetic feeding, insulin therapy affects parameters of protein kinetics and when given in doses suf®cient to normalize glycaemia it induces nitrogen retention in previously moderately hyperglycaemic persons with Type 2 diabetes mellitus. The responses to a VLED of high quality protein in amounts that provide 1.5 g/kg BMI 25 /d combined with insulin therapy during which plasma glucose concentrations are maintained at very near-normal values throughout was re¯ected in less cumulative nitrogen losses than we had observed in diabetic subjects on either a collagen-based, poorer quality or a casein-soy, higher quality protein VLED and not different from those of the obese control subjects. With insulin therapy, less cumulative nitrogen loss was observed during weeks 1 and 2, and was comparable to the obese controls. Furthermore, by week 4, nitrogen balance was not different from zero. The data presented suggest that in Type 2 diabetes the presence of moderate hyperglycaemia is an indicator of a metabolic state in which the turnover of dietary and endogenous protein is altered. It can be restored partially with small doses or completely with insulin suf®cient to achieve euglycaemia. It is affected by the amount of protein provided. When confronted by severe energy restriction, a generous protein intake combined with insulin improves nitrogen retention in such patients.
